Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPLACE: Regorafenib + Pembrolizumab vs TACE/TARE in Intermediate-Stage HCC Beyond Up-to-7 Criteria
KCT0009093Phase 3Terminated
- Sponsor
- Translational Research In Oncology
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of regorafenib and pembrolizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Translational Research In Oncology. Started Aug 2024; status: terminated.
02
Drugs
regorafenibpembrolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0009093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009093.